About the SWITCH-UP Study

The SWITCH-UP Study is evaluating the safety and efficacy of an approved drug compared to another approved drug in participants with atopic dermatitis (AD).
The SWITCH-UP Study is evaluating the safety and effectiveness of an approved drug compared to another approved drug in participants with atopic dermatitis (AD).
Learn More

About the
 SWITCH-UP Study

The SWITCH-UP Study is evaluating the safety and effectiveness of an approved drug compared to another approved drug in participants with atopic dermatitis (AD).

You may be able to participate in the SWITCH-UP Study if you:

Are 18 to 63 years of age

Were diagnosed with AD at least 3 years ago

Haven’t seen enough improvement from a previous AD treatment used for at least 4 months

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you and answer any questions you may have.

Study Overview

The SWITCH-UP Study will involve 9 study visits and 4 phone calls over the course of up to 9 months. There is no placebo in this research study—participants will always be on an active treatment that will be adjusted or changed depending on their clinical response. Participants may be reimbursed for travel and expenses.
Atopic Dermatitis Clinical Research Study
Privacy Policy Legal Notice
© 2025 Clinical Trial Media. All Rights Reserved.
The images depicted contain models and are being used for illustrative purposes only.
About Atopic Dermatitis About Clinical Research The SWITCH-UP Study FAQs Additional Participant Resources

Empower your journey with atopic dermatitis.

See If You May Qualify
844-995-1780

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies, and cookies can only be disabled by changing your browser preferences. 

For more detailed information on the cookies we use, please check our Privacy Policy. 

By continuing to access this website, you are giving us consent to collect cookies.

Accept